Atherosclerosis
Volume 204, Issue 2 , Pages 608-611 , June 2009

Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women

  • M. Shargorodsky

      Affiliations

    • Department of Endocrinology, Wolfson Medical Center, Tel Aviv, Israel
    • The Brunner Institute for Cardiovascular Research, Tel Aviv, Israel
    • Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Corresponding Author InformationCorresponding author at: Wolfson Med Center, POB 5, Holon, 58100, Israel. Tel.: +972 3 5028614; fax: +972 3 5032693.
    • ,
  • M. Boaz

      Affiliations

    • The Brunner Institute for Cardiovascular Research, Tel Aviv, Israel
    • Department of Epidemiology and Statistics, Wolfson Medical Center, Tel Aviv, Israel
    • ,
  • A. Luckish

      Affiliations

    • Department of Medicine, Wolfson Medical Center, Tel Aviv, Israel
    • ,
  • Z. Matas

      Affiliations

    • The Brunner Institute for Cardiovascular Research, Tel Aviv, Israel
    • Department of Biochemistry, Wolfson Medical Center, Tel Aviv, Israel
    • ,
  • D. Gavish

      Affiliations

    • The Brunner Institute for Cardiovascular Research, Tel Aviv, Israel
    • Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Department of Medicine, Wolfson Medical Center, Tel Aviv, Israel
    • ,
  • M. Mashavi

      Affiliations

    • Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Department of Medicine, Wolfson Medical Center, Tel Aviv, Israel

Received 31 August 2008 ,Revised 16 October 2008 ,Accepted 16 October 2008.

References 

  1. Schoppet M, Preissner KT, Hofbauer LC. RANK Ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Tromb Vasc Biol. 2002;22:549–553
  2. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–1268
  3. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192–1194
  4. Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88:1024–1028
  5. Browner WS, Lui L-Y, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86:631–637
  6. Kim SM, Lee J, Ryu OH, et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol. 2005;63:594–599
  7. Emanuele E, Peros E, Scioli GA, et al. Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. Int J Mol Med. 2004;13(6):849–853
  8. van Popele NM, Grobbee DE, Bots ML, et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke. 2001;32:454–460
  9. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–1241
  10. Asmar RG, London GM, O’Rourke MF, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001;38:922–926
  11. O’Rourke M, Staessen JA. Clinical application of arterial stiffness definitions and reference values. Am J Hypertens. 2002;15:426–444
  12. Xiang G, Xu L, Zhao L, Yue L, Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilatation in type 2 diabetes. Diabetes. 2006;55:2126–2131
  13. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiac disease. Circulation. 2004;109:2175–2180
  14. Mangiafico RA, Alagona C, Pennisi P, et al. Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women. Osteoporosis Int. 2008;19:49–56
  15. Malyankar UM, Scatena M, Suchland KL, et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000;14:20959–20962
  16. Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification?. Lancet. 2001;358:257–259
  17. Schiffrin EL. Vascular stiffening and arterial compliance. Am J Hypertens. 2004;17:39–48

PII: S0021-9150(08)00757-0

doi: 10.1016/j.atherosclerosis.2008.10.024

Atherosclerosis
Volume 204, Issue 2 , Pages 608-611 , June 2009

Article Tools

* Image Usage & Resolution